Chronic Inflammation and Disease Risk

Chronic low-grade inflammation is now recognized as a contributing factor in many major diseases — including heart disease, type 2 diabetes, Alzheimer's disease, and certain cancers. EGCG's anti-inflammatory action operates through multiple pathways that distinguish it from conventional anti-inflammatory compounds.

Unlike NSAIDs (non-steroidal anti-inflammatory drugs) that primarily target cyclooxygenase (COX) enzymes, EGCG works upstream by inhibiting NF-κB activation. Since NF-κB is a "master switch" controlling the expression of dozens of inflammatory genes, blocking it has a broad, cascading effect on the inflammatory response.

Evidence From Clinical Studies

• A 2019 randomized controlled trial in patients with rheumatoid arthritis found that 500mg of EGCG daily for 12 weeks significantly reduced disease activity scores, C-reactive protein (CRP), and tender joint counts compared to placebo.

• A study in overweight adults showed that EGCG supplementation (400mg/day) reduced circulating levels of IL-6 and TNF-α after 8 weeks.

• Research on skin inflammation has demonstrated that topical EGCG application reduces UV-induced inflammation and oxidative damage, supporting its use in dermatological applications.

These findings suggest that EGCG's anti-inflammatory effects are clinically meaningful at doses achievable through regular matcha consumption or standardized supplementation.